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Abstract
Background: The World Health Organization (WHO) has established a set of items related to
study design and administrative information that should build the minimum set of data in a study
register. A more comprehensive data set for registration is currently developed by the Ottawa
Group. Since nothing is known about the attitudes of academic researchers towards prospective
study registration, we surveyed academic researchers about their opinion regarding the
registration of study details proposed by the WHO and the Ottawa Group.
Methods: This was a web-based survey of academic researchers currently running an investigator-
initiated clinical study which is registered with clinicaltrials.gov. In July 2006 we contacted 1299
principal investigators of clinical studies by e-mail explaining the purpose of the survey and a link to
access a 52-item questionnaire based on the proposed minimum data set by the Ottawa Group.
Two reminder e-mails were sent each two weeks apart. Association between willingness to
disclose study details and study phase was assessed using the chi-squared test for trend. To explore
the potential influence of non-response bias we used logistic regression to assess associations
between factors associated with non-response and the willingness to register study details.
Results: Overall response was low as only 282/1299 (22%) principal investigators participated in
the survey. Disclosing study documents, in particular the study protocol and financial agreements,
was found to be most problematic with only 31% of respondents willing to disclose these publicly.
Consequently, only 34/282 (12%) agreed to disclose all details proposed by the Ottawa Group.
Logistic regression indicated no association between characteristics of non-responders and
willingness to disclose details.
Conclusion: Principal investigators of non-industry sponsored studies are reluctant to disclose all
data items proposed by the Ottawa Group. Disclosing the study protocol and financial agreements
was found to be most problematic. Future discussions on trial registration should not only focus
on industry but also on academic researchers.
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Since 2005 the International Committee of Medical Jour-
nal Editors (ICMJE) has required prospective registration
of clinical studies in order to be considered for publica-
tion in one of their journals [1]. Moreover, the World
Health Organization (WHO) has established a set of
items related to study design and administrative informa-
tion that should form the minimum set of data in a study
register [2]. Several stakeholders were consulted on this
WHO Trial Registration Data Set including academic
researchers, industry and patient representatives. How-
ever, several items were highly controversial and industry
representatives demanded that some items should not be
disclosed during study conduct [3]. Industry representa-
tives argued that some trial information is sensitive for
competitive reason and asked for delayed disclosure of
some items e.g. the scientific title of a study, primary and
secondary outcomes. However, competition is also of
increasing importance in academic research [4].
In 2005 the Ottawa Group published principles of trial
registration [5] and a minimum data set for registration is
currently being developed [6]. This set requires even more
details about a study than the WHO Trial Registration
Data Set (see Table 1). However, analyses of trial registra-
tion in ClinicalTrials.gov showed heterogeneous quality
and completeness of the registration entries indicating
varying degrees of comfort with different levels of disclo-
sure [7]. Since nothing is known about the attitudes of
academic researchers towards prospective study registra-
tion, it is unclear if they would comply with an extension
of the requested study information. We therefore surveyed
academic researchers about their opinions regarding the
registration of study details proposed by the Ottawa
Group.
Methods
Study design
This study was a survey of academic researchers currently
running investigator-initiated clinical studies which were
registered with clinicaltrials.gov. It was approved by the
ethics committee of the University of Göttingen, Ger-
many.
Study population
The basic population consisted of all recruiting or
planned investigator-initiated clinical studies registered
with the study register of the U.S. National Institutes of
Health (clinicaltrials.gov) in May 2006 (n = 7988). Using
computer generated random numbers we selected 1500
studies. Investigator-initiated studies were defined as all
studies which were registered with a non-industry spon-
sor. In July 2006, all principal investigators with valid
contact details were contacted by e-mail explaining the
purpose of the survey and a link to access the question-
naire. Two reminder e-mails were sent each two weeks
apart. No attempts were made to contact non-responders
by phone because of difficulties to obtain sufficient con-
tact details and resource constraints. Written informed
consent was not sought in this internet based survey but
informed consent of participants was implied because
access to the questionnaire was restricted to persons
approached by e-mail explaining the study.
Data collection
A web-based 52-item questionnaire was developed based
on the WHO Trial Registration Data Set [2] and the pro-
posed minimum data set from the Ottawa Group [6]. Par-
ticipants were asked whether they would be willing to
publicly disclose specific details about their study. The
questionnaire consisted of eleven main sections (Addi-
tional file 1): Contacts and funding, title and description
of the study, key dates, ethical approval, background of
the study, eligibility criteria, intervention(s), outcome
Table 1: Study details required by WHO and Ottawa Group
WHO Trial Registration Data 
Set
Ottawa Group Data Set (in addition 
to WHO items)
Trial registration date Trial acronym
Ethics approval Trial website
Funding source(s) Lay description
Primary sponsor Registration date
Secondary sponsor(s) Date ethical approval
Coordinating/principle 
investigator
Date recruitment end
Contact person Date end of follow-up
Coordinating center Date trial stop
Recruitment center locations Trial extensions
Official scientific title Date primary analyses
Lay title Name of Research ethics board/
institutional
Date recruitment start Review board (REB/IRB)
Recruitment status REB trial approval number
Inclusion criteria Rationale of the trial
Exclusion criteria References to systematic reviews
Disease/condition Justification of interventions
Interventions Trial objectives
Primary endpoint Study design
Secondary endpoints Number of arms
Trial phase/study type Generation of allocation sequence
Target sample size Randomization
Allocation concealment
Blinding status
Other design features
Framework of the study
Sample size calculation
Planned subgroup analyses
Planned analyses methods
Consent forms
Full protocol
Contracts and financial 
arrangementsPage 2 of 6
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response categories to indicate willingness for disclosure:
yes, no, don't know/can't decide, don't want to answer,
not applicable. Each question had to be answered in order
to proceed with the questionnaire. Given that the ques-
tionnaire solely consisted of questions directly related to
items of the two data sets mentioned above, no piloting of
the questionnaire was done.
Sample size calculation
Sample size calculation was based on confidence intervals
for proportions and the following considerations: 1) a
maximum width of a confidence interval for questions
answerable dichotomously of 6% was considered narrow
enough; 2) based on a basic population of 7988 this
would require 259 responses; 3) assuming a response rate
of 25% a sample size of 1036 would be needed; 4) to
account for missing and invalid contact details we selected
1500 studies.
Statistical analysis
Data were analysed in Stata 9.2 using descriptive statistics
for the main analysis. Responders and non-responders
were compared using the chi-squared test. Association
between willingness to disclose study details and study
phase was assessed using the chi-squared test for trend. To
explore the potential influence of non-response bias we
used logistic regression to assess associations between fac-
tors associated with non-response and the willingness to
register study details. We therefore included the following
factors in the regression analysis: study sponsored by the
National Institutes of Health and phase II study in oncol-
ogy. For ease of interpretation we recoded "yes" and "not
applicable" responses as 'yes' and "no", "don't want to
answer", and "don't know" as 'no'. We chose this coding
procedure in order to predict willingness to disclose all
study details according the Ottawa criteria. Coding "not
applicable" as "no" would have had the following poten-
tial consequence: e.g. if a participant is willing to disclose
the whole data-set except one item which is not applicable
to his context, he would have been falsely categorized as
completely reluctant (i.e. "0" in regression analysis).
Results
201 out of the initial 1500 studies had no (n = 184) or no
valid (n = 17) e-mail address of the principal investigator
available, leaving 1299 potential participants. Studies
with principal investigators with no or invalid e-mail
address were more likely to be sponsored by the National
Institutes of Health, to be in the field of oncology, and
more likely to study a drug. Of the 1299 contacted inves-
tigators, 282 (22%) responded and these formed the pop-
ulation for analysis (Figure 1).
Non-responders were more likely to be principal investi-
gators of studies sponsored by the National Institutes of
Health (Table 2). Studies of non-responders were also
more likely to be in the field of oncology and registered as
phase II studies. Given these differences in responders and
non-responders, we did not calculate confidence intervals
of response distributions.
Agreement to disclose study details was very high for most
individual items (Additional file 1). Willingness to regis-
ter study details was lowest for details of planned sub-
group analyses (49% willingness to register), sample size
calculation (57%), and planned analyses methods (58%).
However, disclosing study documents, in particular the
study protocol and financial agreements, was found to be
most problematic with only 31% of respondents willing
to disclose these publicly. 151 investigators (54%) would
be willing to present results of their studies in a register.
However, only 89 participants (32%) would be willing to
present results before submission to a peer-reviewed jour-
nal even if journal editors would accept such a presenta-
tion (a situation that would be comparable to today's
practice regarding presentation at conferences).
Sixty-eight responders (24%) were willing to disclose all
items required by the WHO – and clinicaltrials.gov. Only
34/282 (12%) agreed to disclose all details proposed by
the Ottawa Group (Figure 2).
If disclosing documents would not be required, 67/282
(24%) participants would be willing to disclose all other
details. Not requiring registration of planned analyses
methods including subgroup analyses only slightly
Study flow diagramFigure 1
Study flow diagram.
Studies randomly selected
N=1500
Principal investigators successfully invited
N=1299
No e-mail address, N=184
E-mail address invalid, N=17
No response, N=1017
Participation in the survey
N=282Page 3 of 6
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data set to study details not identified as sensitive for com-
petitive reasons by industry (scientific title, intervention,
sample size calculation, outcome measures) also
increased this proportion only slightly (71/282; 25%).
There was no association between study phase and will-
ingness to register details according to the data set pro-
posed by the Ottawa Group (test for trend p = 0.59).
Logistic regression indicated no association between char-
acteristics of non-responders (study sponsored by the
National Institutes of Health and phase II study in oncol-
ogy) and willingness to disclose details (p > 0.15 for each
explanatory variable).
Discussion
This is the first survey on opinions of academic researchers
suggesting that principal investigators of non-industry
sponsored studies are reluctant to disclose all data items
proposed by the Ottawa Group. Disclosing the study pro-
tocol and financial agreements were found to be most
problematic.
Table 2: Study characteristics
Variables Total E-mail available* E-mail not available p** Responders Non-responders p
Recruiting status of study 1500 1299 201 0.15 282 1017 0.68
Recruiting 1375 (91.7) 1196 (92.1) 179 (89.0) 258 (91.5) 938 (92.23)
Not yet 125 (8.3) 103 (7.9) 125 (8.3) 24 (8.5) 79 (7.8)
Type of sponsor <0.001 <0.001
NIH 288 (19.2) 207 (15.9) 81 (40.3) 21 (7.4) 186 (18.3)
Other 1212 (80.8) 1092 (84.1) 120 (59.7) 261 (92.5) 831 (81.7)
Study condition according to ICD 10 <0.001 0.03
Infections 69 (4.6) 64 (4.9) 5 (2.5) 22 (7.8) 42 (4.1)
Oncology 608 (40.5) 474 (36.5) 134 (66.7) 73 (25.9) 401 (39.4)
Haematology 23 (1.5) 19 (1.5) 4 (2.0) 3 (1.1) 16 (1.6)
Endocrinologic diseases 85 (5.7) 79 (6.1) 6 (3.0) 21 (7.4) 58 (5.7)
Psychiatric diseases 119 (7.9) 109 (8.4) 10 (4.9) 28 (9.9) 81 (8.0)
Neurologic diseases 62 (4.1) 58 (4.6) 4 (2.0) 14 (5.0) 44 (4.3)
Eye 12 (0.8) 2 (1.0) 10 (0.8) 2 (0.7) 8 (0.8)
Ear 2 (0.1) 2 (0.1) 0 (0.0) 1 (0.3) 1 (0.1)
Cardiovascular diseases 123 (8.2) 118 (9.1) 5 (2.5) 30 (10.6) 88 (8.6)
Lung diseases 59 (3.9) 53 (4.1) 6 (3.0) 10 (3.5) 43 (4.2)
Digestive diseases 43 (3.3) 4 (2.0) 47 (3.1) 15 (5.2) 28 (2.7)
Skin 19 (1.3) 18 (1.4) 1 (0.5) 3 (1.1) 15 (1.5)
Musculoskeletal disorders 51 (3.4) 48 (3.7) 3 (1.5) 12 (4.3) 36 (3.5)
Urology 76 (5.1) 72 (5.5) 4 (2.0) 20 (7.1) 52 (5.1)
Pregnancy 26 (1.7) 23 (1.8) 3 (1.5) 5 (1.8) 18 (1.8)
Perinatal disorders 10 (0.7) 10 (0.8) 0 (0.0) 3 (1.1) 7 (0.7)
Labour 2 (0.1) 2 (0.1) 0 (0.0) 1 (0.3) 1 (0.1)
Trauma 39 (2.6) 35 (2.7) 4 (2.0) 6 (2.1) 29 (2.8)
Extern 1 (0.1) 1 (0.1) 0 (0.0) 1 (0.3) 0 (0.0)
Other 67 (4.5) 61 (4.7) 6 (3.0) 12 (4.3) 49 (4.8)
Study intervention <0.001 0.10
Drug 895 (59.7) 741 (57.0) 154 (76.6) 143 (50.7) 598 (58.8)
Procedure 231 (15.4) 211 (16.2) 20 (9.9) 55 (19.5) 156 (15.3)
Behaviour 112 (7.5) 107 (8.2) 5 (2.5) 32 (11.3) 75 (7.4)
Device 64 (4.3) 62 (4.8) 2 (1.0) 14 (5.0) 48 (4.7)
Vaccine 17 (1.1) 12 (0.9) 5 (2.5) 3 (1.1) 9 (0.9)
Gene therapy 5 (0.3) 4 (0.3) 1 (0.5) 0 (0.0) 4 (0.4)
Other/not applicable 176 (11.7) 162 (12.5) 14 (7.0) 35 (12.4) 127 (12.5)
Study phase <0.001 <0.01
Phase I 137 (9.1) 113 (8.7) 24 (11.9) 19 (6.7) 94 (9.2)
Phase II 357 (23.8) 281 (21.6) 76 (37.8) 45 (16.0) 236 (23.2)
Phase III 230 (15.3) 206 (15.9) 24 (11.9) 51 (8.1) 155 (15.2)
Phase IV 177 (11.8) 168 (12.9) 9 (4.5) 48 (17.0) 120 (11.8)
Phase I/II 72 (4.8) 56 (4.3) 16 (8.0) 6 (2.1) 50 (4.9)
Phase II/III 43 (2.9) 35 (2.7) 8 (4.0) 6 (2.1) 29 (2.8)
Not applicable 484 (32.3) 440 (33.9) 44 (21.9) 107 (37.9) 333 (32.7)
* E-mail address of principal investigator
** Chi-squared test
Categories with less than six counts overall were added to category "Other" or "Other/not applicable" for the chi-square test.Page 4 of 6
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response bias. The response rate was low with only 22%
of potential participants responding. It is well known that
web-based surveys have lower response rates than postal
surveys [8]. Exact reasons for this low response rate
remain unclear for us but might be related to the length of
the questionnaire, the absence of any incentive, or the
topic itself [9]. Nevertheless, we found no association
between characteristics associated with non-response and
the willingness to disclose study details. Although the
impact of non-response seems therefore less problematic
this study should be viewed as exploratory. Socially desir-
able responses might be another problem often encoun-
tered in surveys. Drawing conclusions about the actual
habit of respondents is therefore often problematic [10].
Given the recent debate about trial registration and the
requirement of editors of major journals to register a clin-
ical study, one might expect that respondents would
favour registration simply to conform with opinion lead-
ers. The high proportion of respondents willing to dis-
close individual study details might be viewed as an
indication for socially desired response habit. However,
willingness to disclose all proposed items was low indicat-
ing that respondents differentiated well between different
items. Finally, because of limited information available,
we were not able to explore characteristics of investigators
willing to disclose study details such as country of origin
or host institution.
Recent debates about the WHO Trial Registration Data Set
have focused on the reluctance of industry to disclose par-
ticular study details [11,12]. Representatives of industry
argue that some study details are sensitive for competitive
reasons and that these details might be disclosed with
some delay [13]. However, academic research is also com-
petitive nowadays and researchers might therefore also be
reluctant to disclose study details. This reluctance might
be even more pronounced for study registers adopting the
data set proposed by the Ottawa Group [6]. The main rea-
sons for prospective trial registration correspond to publi-
cation and outcome reporting bias [14,15]. For example,
trial participants are at risk of being misled when their
consent and the trial design are not fully informed by
prior research or institutional review board (IRB) mem-
bers cannot fully weigh risks and benefits when some
unknown proportion of the relevant data is unavailable
for review [16]. Consequently, it is an ethical obligation of
researchers to publish all relevant details of their clinical
studies and publicly available clinical study registers help
to fulfil this obligation [17].
Conclusion
As our survey suggests, academic researchers might be
reluctant to disclose details of their study. Future discus-
sions on trial registration should not only focus on indus-
try but also on academic researchers. Consequences of
more detailed registration of studies should be openly dis-
cussed when considering a minimum data set for a given
trial register. These potential consequences not only
include issues related to commercial and academic com-
petition but also the increasing administrative workload
of clinical researchers. Lastly, it seems important to dis-
seminate the ethical obligation to register clinical studies
more broadly.
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